Editorial: adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease

B. Christensen, M. P. Sparrow

Research output: Contribution to journalEditorialOtherpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)178-179
Number of pages2
JournalAlimentary Pharmacology & Therapeutics
Volume45
Issue number1
DOIs
Publication statusPublished - 1 Jan 2017

Cite this